Pharmaceutical excipient specialist DFE Pharma has achieved ISO 22301 certification for its BCMS system at its head office in Goch, Germany.
The ISO 22301 certification is given to companies who follow a rigorous and independent third-party assessment, which evaluates a business' functionality and infrastructure.
The programme is prepared to safeguard operations and maintain global supply chains, ensuring that pharmaceutical manufacturers have consistent access to excipients.
By completing this auditing process, DFE Pharma proves its preparedness for responding to disruptions and sustaining operations continuity.
Building a robust BCMS has been a core focus for DFE Pharma for an extended period — allowing the company to respond to disruptions and fortify its operations so the company can continue to serve its customers during crises.
By implementing this technology, DFE Pharma hopes to rapidly respond to disruptions, minimise downtime and reduce recovery time.
"In light of increasing global uncertainty, ensuring business continuity in periods of instability has become more crucial than ever," commented CEO of DFE Pharma, Sven Abend.
"Our achievement of ISO 22301 certification highlights our proactive approach to business continuity management, meaning our customers can be confident that we will mitigate risks, prevent disruptions and guarantee the consistent supply of our excipients," he concluded.